ロード中...
非小细胞肺癌EGFR突变的分子影像学在体检测
An ever increasing number of drugs directed as epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) bring a new revolution for non-small cell lung cancer (NSCLC) therapy, and many large scales of studies show that only people with EGFR-sensitive mutation can benefit from these drugs...
保存先:
| 出版年: | Zhongguo Fei Ai Za Zhi |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
中国肺癌杂志编辑部
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5973363/ https://ncbi.nlm.nih.gov/pubmed/28641700 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.08 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|